HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MRVL
Marvell Technology, Inc.
MRVL's fundamentals are strong, but it looks expensive: trading at 54x earnings, about twice its usual 25x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MRVL Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Healthy |
MRVL's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MRVL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | $51.02 | -69% |
| Fair | 25x | $75.19 | -54% |
| Forward | 25x | $164 | — |
| Current | 54x | $164 | — |
| Expensive | 71x | $215 | +31% |
Historical ranges are pointers, not guarantees.
MRVL's PE is in its expensive range at 54x. If earnings grow as analysts expect, today's price would be 25x next year's earnings, in its fair range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MRVL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
MRVL has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MRVL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $6.51 | +116% |
| Q3 2026 | $3.02 | +$3.15 |
| Q2 2026 | $2.91 | +$3.48 |
| Q1 2026 | $3.07 | +$4.09 |
| Q4 2025 | $2.85 | +$4.55 |
| Q3 2025 | -$0.13 | +$0.98 |
| Q2 2025 | -$0.57 | +$0.56 |
| Q1 2025 | -$1.02 | +$0.06 |
| Q4 2024 | -$1.70 | -$1.05 |
MRVL has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MRVL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MRVL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.7B | +37% |
| Q2 2026 | $2.4B | +28% |
| Q1 2026 | $2.2B | +22% |
| Q4 2025 | $2.1B | +37% |
| Q3 2025 | $2B | +58% |
| Q2 2025 | $1.9B | +63% |
| Q1 2025 | $1.8B | +27% |
| Q4 2024 | $1.5B | +6.9% |
MRVL's revenue has grown year over year for eight quarters in a row: $2.7B last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +2.3 points |
| Q2 2026 | 14% | -0.2 points |
| Q1 2026 | 18% | +5.3 points |
| Q4 2025 | 17% | +64 points |
| Q3 2025 | 14% | +22 points |
| Q2 2025 | 14% | +27 points |
| Q1 2025 | 13% | +15 points |
| Q4 2024 | -46% | -36 points |
MRVL has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MRVL on cash flow, with more consistent year-over-year improvement.
MRVL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $478.8M | +16% |
| Q2 2026 | $483.1M | +126% |
| Q1 2026 | $259.4M | -42% |
| Q4 2025 | $508.8M | +10% |
| Q3 2025 | $414.1M | +60% |
| Q2 2025 | $214.1M | -8.1% |
| Q1 2025 | $444.1M | -6.6% |
| Q4 2024 | $461.3M | +2.8% |
MRVL generated $1.7B in free cash flow over the past year, up 13% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MRVL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MRVL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.1% | +27.9M shares |
| 1 year | +5.8% | +50.8M shares |
| 3 years | +7% | +60.3M shares |
| 5 years | +12% | +100M shares |
| Available history | +38% | +253M shares |
MRVL has 921M diluted shares, up 5.8% from a year ago, despite $1.9B in buybacks over the past year.
| Quarter | Spent |
|---|---|
| Q3 2026 | $200M |
| Q2 2026 | $200M |
| Q1 2026 | $200.1M |
| Q4 2025 | $1.3B |
| Q3 2025 | $200M |
| Q2 2025 | $340M |
| Q1 2025 | $200M |
| Q4 2024 | $200M |
MRVL spent $1.9B buying back its own shares over the past year, up 102% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MRVL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2021 | 1.5x | Healthy |
| Q4 2020 | 0.5x | Very low |
| Q3 2020 | 0.6x | Very low |
| Q2 2020 | 0.7x | Very low |
| Q1 2020 | 0.7x | Very low |
| Q4 2019 | 5.3x | High |
MRVL's net debt is about 1.5 years of its operating earnings (EBITDA), up from less than a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MRVL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 16.1 | Oversold |
MRVL's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MRVL PE vs Technology Sector
| Metric | MRVL | Sector median | Relative |
|---|---|---|---|
| PE | 54x | 28x | 95% above |
| PE % | 75 | 35 | 40 pts above |
MRVL is trading at 54x earnings, a 95% premium to the Technology sector's median of 28x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MRVL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $221.0 | 26% below |
| 20 week MA | $220.9 | 26% below |
| 50 week MA | $168.8 | 2.5% below |
| 100 week MA | $124.8 | 32% above |
| 200 week MA | $93.8 | 75% above |
MRVL has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MRVL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $26.7 | $47.1 | +76% |
| 2021 | $47.1 | $87.7 | +86% |
| 2022 | $87.7 | $37.2 | -58% |
| 2023 | $37.2 | $60.3 | +62% |
| 2024 | $60.3 | $113.6 | +88% |
| 2025 | $113.6 | $86.3 | -24% |
| 2026 YTD | $86.3 | $164.5 | +90% |
MRVL has the edge over HIMS on returns for 2026, with the stronger performance.